Pharmaceuticals
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an agreement granting Nuance Pharma, aShanghai-based specialty pharmaceutical c...
2021-06-10 14:00
2788
Enamine implements CDD Vault to digitalize its integrated medicinal chemistry, ADME-PK and screening services
The company's expansion in the biological assay space aided by the data platform SAN FRANCISCO and KYIV, Ukraine, June 10, 2021 /PRNewswire/ -- Enamine, a leading provider of R&D Services as well asScreening Compounds, Fragments, Building Blocks and specialized libraries for Drug Discovery, annou...
2021-06-10 13:57
2191
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS,"LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnershi...
2021-06-10 08:30
5778
Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer
SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment ofCharles S. Ryan, JD, PhD as President and Chief Execut...
2021-06-09 21:00
1967
China Pharma to Launch Highly Purified NMN+PQQ Product
HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...
2021-06-09 20:00
10243
European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter
SANDWICH, England, June 9, 2021 /PRNewswire/ -- Sulphobutyl ether β-cyclodextrin (SBE-β-CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical ingredients, prominent among which is the antifungal drug, voriconazole. Working with ProfessorSteve Wick...
2021-06-09 19:50
2247
Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer
SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd. incorporated inSingapore on 7th April 2017, a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment of Charles S....
2021-06-09 13:38
2224
Cytiva opens experience and learning lab in Singapore
* New lab will support Singapore government's Industry 4.0 agenda to build research, digital, innovation capability and talent development * Part of Cytiva's capacity expansion plan to meet the increasing demands for the biopharmaceuticals industry * Through this lab, Cytiva intends to run 7...
2021-06-08 10:00
2268
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL
SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first...
2021-06-08 07:30
5511
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at t...
2021-06-08 07:21
12859
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...
2021-06-07 20:00
7231
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a leading novel, dual-action, investigational COVID-19 oral pill Blinded blended mortality rates encourag...
2021-06-07 19:00
5402
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021
SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...
2021-06-07 10:11
7211
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021
* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...
2021-06-07 10:10
6669
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021
* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...
2021-06-07 09:53
6730
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...
2021-06-07 08:30
4062
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries
ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...
2021-06-07 08:00
2801
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8711
Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
SEOUL, South Korea, June 5, 2021 /PRNewswire/ -- Samsung Pharm Co., Ltd. announced today that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called 'RIAVAX™ (GV1001)' conducted in Korea at the 2021 American Society of Clin...
2021-06-05 20:00
3832
Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
SUZHOU, China, June 4, 2021 /PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophylactic vaccine candidate, inAustralia. The phase 2 study is a two-ce...
2021-06-04 20:05
4208
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 319 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 307 media titles]
2026-04-06 10:00
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 298 media titles]
2026-04-06 16:46
Most Read
Korea's Supreme Court Upholds Korea Zinc's Voting Restriction, Rebuffing Young Poong's Legal Challenge
2026-04-03 21:00
5895
51Talk Marks 15 Years with Global Brand Refresh and Names Thai Actor, Shahkrit Yamnarm as Brand Ambassador in Thailand
2026-04-03 11:00
5642
Xinhua Silk Road: Global South financiers visit E. China's Ningbo to explore industrial and cultural innovation
2026-04-03 20:02
5338
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
2026-04-04 00:00
5105
